These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 9865682

  • 1. Immunization with virus-modified tumor cells.
    Schirrmacher V, Ahlert T, Pröbstle T, Steiner HH, Herold-Mende C, Gerhards R, Hagmüller E, Steiner HH.
    Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
    [Abstract] [Full Text] [Related]

  • 2. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
    Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C.
    Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
    [Abstract] [Full Text] [Related]

  • 3. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V.
    Vaccine; 2005 Mar 31; 23(19):2439-53. PubMed ID: 15752830
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M, Janke M, Lulei M, Beckhove P, Fournier P, Schirrmacher V.
    Int J Oncol; 2008 Apr 31; 32(4):777-89. PubMed ID: 18360705
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
    Fournier P, Zeng J, Von Der Lieth CW, Washburn B, Ahlert T, Schirrmacher V.
    Int J Oncol; 2004 Mar 31; 24(3):623-34. PubMed ID: 14767547
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
    Fournier P, Aigner M, Schirrmacher V.
    Int J Oncol; 2010 Nov 31; 37(5):1203-17. PubMed ID: 20878068
    [Abstract] [Full Text] [Related]

  • 11. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.
    Termeer CC, Schirrmacher V, Bröcker EB, Becker JC.
    Cancer Gene Ther; 2000 Feb 31; 7(2):316-23. PubMed ID: 10770642
    [Abstract] [Full Text] [Related]

  • 12. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
    Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V.
    Int J Oncol; 2005 Feb 31; 26(2):431-9. PubMed ID: 15645128
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov 31; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA, Neelapu SS, Kwak LW, Biragyn A.
    Haematologica; 2002 Sep 31; 87(9):989-1001. PubMed ID: 12217812
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.